Earnout Collection Rates: Why DTC Sellers Get Paid Less

Selling a direct-to-consumer (DTC) brand almost always means an earnout: a slice of the price the buyer pays only if the business hits agreed targets after close. On paper it looks like a bigger number. In practice, across private-target, non-life-sciences M&A, sellers collect about 21 cents on every dollar of stated earnout (SRS Acquiom 2024 M&A Claims Insights Report). And 41% of earnout deals pay nothing at all. If you are running a $5M to $15M brand and a buyer is dangling a headline price built on an earnout, the honest read is that the cash at close is the real deal, and the earnout is a lottery ticket you can improve the odds on but should not bank on.

This post walks through the actual collection data, the three levers buyers pull to miss your target, why EBITDA triggers are especially dangerous for DTC sellers, and the six covenants that shift risk back to the buyer before you sign.

What an earnout actually is (and why buyers love them)

An earnout is a contingent post-close payment tied to hitting a revenue or EBITDA target, usually over 12 to 24 months. Buyers love them because they transfer risk. A buyer looking at a fast-growing DTC brand cannot fully underwrite whether the growth is durable or a paid-traffic sugar high, so they pay a fair number in cash and put the rest behind a target. If the growth is real, they pay. If it is not, they keep the money.

A typical sub-$25M DTC structure looks like this: an $8M total deal is $5.6M cash at close plus a $2.4M earnout on Year 1 revenue clearing, say, $6M. The total headline number is where the earnout hides, which is why it pays to understand what your brand is actually worth on an EV/Revenue and EV/EBITDA basis before you agree to how the price is split. The earnout usually runs 18% to 35% of total consideration. The 2024 median earnout is 31% of closing payments, down slightly from 34% in 2023. The median earnout period is 24 months.

Earnout prevalence itself tells you something. Earnouts appeared in about 15% of deals in 2019, surged to a 30% to 37% peak in 2023 as the valuation gap between hopeful sellers and cautious buyers widened after 2022 rate rises, then moderated to roughly 22% in 2024. They show up precisely when buyer and seller disagree on what the business is worth, and that disagreement is baked in before you even negotiate the metric.

When I talk to founders selling a brand this size, the thing they consistently underestimate is how completely control shifts at close. The business that hits the target is no longer the business you ran. It is the business the buyer runs, measured on a number they influence daily.

The real collection rate: what the data shows

Start with the headline. SRS Acquiom's 2024 report, covering more than 850 private-target acquisitions and 200 earnout milestones, found that earnouts pay out about 21 cents per dollar of stated earnout value across non-life-sciences deals. Break that down and it gets worse for the lower middle market. About 41% of deals pay zero. Of the roughly 59% that pay anything, the median payout is only about half the maximum. And SRS Acquiom explicitly notes that deals valued at $50M or less "generally see lower earnout achievement rates" than larger transactions, which is exactly the bracket where DTC brands sell.

Run the math on a real deal. A $10M sale with a $3.1M earnout (the 31% median applied exactly) is $3.1M of your price sitting in a contingent bucket. At the aggregate collection rate you would statistically expect to collect around $650K of that $3.1M. In the lower middle market, plan for less. That is not a reason to refuse an earnout. It is a reason to structure it so your odds beat the average and to price the cash at close as the number you can actually count on. This is exactly the work an interim CFO does alongside your M&A advisor: modeling the expected collection, not the promised one, before you sign.

The three levers buyers pull to miss your target

The collection data is not bad luck. It is the mechanical result of who holds the controls after close. Three levers do most of the damage.

One: marketing spend cuts. In a DTC brand, paid social and search drive a disproportionate share of revenue. A buyer who trims ad spend by 30% post-close, common when a private-equity firm or aggregator folds the brand into a shared cost structure, can easily cause a 15% to 25% revenue shortfall. With no marketing floor in the contract, there is no recourse. One founder who sold a health-supplement brand in the $8M to $12M range described discovering that the acquirer had shifted the brand's paid-social budget to other portfolio brands within 60 days, before the first measurement period had even closed. There was nothing in the agreement that stopped it.

Two: overhead allocation and EBITDA engineering. Buyers add shared-services fees, corporate overhead, parent-company IT costs, and insurance allocations to the acquired entity's P&L. A common pattern in post-close reviews is that sellers forfeit a large share of an EBITDA-based earnout through expense allocation alone, expenses that were never in the pre-close financials. When we talk to operators who have been through this, the phrasing repeats almost word for word: "at the time we thought we were getting a higher headline number; in hindsight we gave them a dial to turn."

Three: operational interference. Buyers change pricing (which moves DTC revenue), shift channels so revenue leaves the measured entity, terminate the founder or CMO whose relationships drove growth, or time invoices around the measurement cutoff. Delaware courts have started treating the more aggressive versions of this as bad faith. In Jiggy Puzzles v. Steelhead Acquisition (Del. Super., Feb. 2026), the court examined documented internal "game time decisions" to avoid an earnout trigger. In Monica v. Delta Data Software (Del. Super., Feb. 2026), an implied-covenant claim over deliberately delayed customer payments survived a motion to dismiss. The bar is high, but the affirmative-bad-faith path exists.

Why EBITDA triggers are particularly dangerous

The single biggest structural decision in an earnout is the metric. Revenue-based earnouts are the dominant structure precisely because revenue is harder to manipulate; practitioner estimates (Livmo analysis of SRS Acquiom data) put revenue at around 62% of deals, with EBITDA-only at about 22%, though no primary source publishes an exact split.

The problem with EBITDA is that it is a bottom-line number the buyer influences from both sides. Revenue can hold up while EBITDA collapses under allocated costs you never agreed to. If you accept an EBITDA trigger without negotiating a minimum marketing spend floor, a cap or exclusion on parent-company overhead, and an explicit EBITDA definition with agreed add-backs, you have handed the buyer a dial to turn your payout down. Revenue is not bulletproof, a buyer can still shift channels or starve acquisition, but it removes the entire expense-allocation attack surface. The pattern we see again and again: operators who took revenue triggers with tight definitions, net revenue, specific SKUs or channels, no inter-company transfers, had far fewer disputes than those who took EBITDA on a handshake about "normal" cost allocation.

Six tactics that shift risk back to the buyer

You cannot change the base rates, but you can change your deal, and how well you structure the terms before signing has a direct bearing on your overall exit value. Here is the checklist worth fighting for before signing.

1. Choose revenue over EBITDA whenever possible. It is harder to manipulate, easier to verify, and faster to dispute. Its dominance as the preferred metric is not an accident.
2. Mandate a marketing spend floor. Specify a minimum dollar amount or percentage of revenue the buyer must spend on paid acquisition during the earnout, and lock in headcount for the roles that drive it.
3. Write explicit cost-allocation rules. Define exactly which shared-services charges can hit the earnout entity's P&L. Cap or exclude parent-company overhead. This is the single most valuable covenant on an EBITDA deal.
4. Negotiate an acceleration clause. If the buyer sells or transfers the business during the earnout, the full remaining earnout becomes immediately payable. Roughly a quarter of non-life-sciences deals now include this, so it is on the table.
5. Name an independent accountant for disputes. Put the firm in the purchase agreement. Calculation disputes are the most common earnout fight, and naming the referee up front avoids expensive litigation.
6. Prefer cumulative over annual targets. A 24-month cumulative revenue target is harder to game than two separate annual targets, where a buyer can sacrifice Year 1 to bank Year 2.

The earnout is not a bonus on top of your sale price. It is a portion of your sale price the buyer gets to keep if the business you no longer control misses a number they largely set. Treat the cash at close as the deal, treat the earnout as an option, and spend your negotiating capital on the covenants, spend floors, cost caps, acceleration, and an independent referee, that move the odds. That is where the money actually is.

What to do if the earnout goes wrong

If you are already in a contested earnout, four moves matter. First, document everything: financial reports, marketing spend, channel decisions, and any communications showing affirmative steps to undermine the target, because that is the standard Delaware applies. Second, invoke your independent-accountant clause before threatening litigation; most fights are calculation disputes that a named referee can settle. Third, understand the implied covenant of good faith: courts will hear claims where a buyer actively sabotaged the payout, as in Fortis Advisors v. Krafton (Del. Ch., March 2026), where a CEO reinstatement was ordered and the earnout period was extended 258 days, but mere inaction usually does not clear the bar. Fourth, weigh mediation before arbitration or a lawsuit; litigation is expensive and outcomes are uncertain, and a negotiated resolution often beats years in court.

The aggregator era added one more risk to the list: buyer solvency. Thrasio filed Chapter 11 in February 2024, eliminating roughly $495M in debt and leaving sellers who were still owed earnout payments exposed. If your buyer is a debt-heavy roll-up, the earnout is only as good as their balance sheet, which is one more reason to weight the cash at close.

Sources and methodology

This post is compiled from a specialist M&A claims database, the leading academic corporate-governance forum, published Delaware court coverage from an international law firm, and dated financial press on the aggregator segment, all linked below. Operator context is drawn from anonymized post-close reviews of DTC founders who have been through a sale; no client or company is named.

SRS Acquiom 2024 M&A Claims Insights Report is the primary source for the payout data. The report analyzes 850+ private-target acquisitions worth roughly $168B, including 200 earnout milestones, and reports the ~21-cent collection rate, the ~59% any-payment rate, the 28% dispute rate, and the 17% renegotiation rate. See the SRS Acquiom M&A Claims Insights Report and the SRS Acquiom earnouts overview.

The Harvard Law School Forum on Corporate Governance summarizes the prevalence and structure data. Its July 2025 piece cites the SRS Acquiom Deal Terms Study for earnout prevalence (about 22% in 2024, a 30% to 37% peak in 2023, 15% in 2019), the 31% median earnout share of closing payments, and the 24-month median duration. It confirms revenue is the most popular trigger metric followed by EBITDA, but does not quantify the exact split. See The Art and Science of Earn-Outs in M&A.

Delaware case law grounds the buyer-interference examples. Coverage of the 2026 decisions in Monica v. Delta Data Software, Jiggy Puzzles v. Steelhead Acquisition, and Fortis Advisors v. Krafton is drawn from Reed Smith, Delaware Courts Sharpen Focus on Post-Closing Earn-Out Disputes.

The metric-split and negotiation framework draw on M&A advisory analysis. The approximately 62% revenue prevalence estimate and the six-lever negotiation checklist draw on practitioner sources including Livmo's earnout structuring analysis. The 24-month median duration is sourced from Harvard Corp Gov / SRS Acquiom. Note: no primary source publishes a precise revenue vs. EBITDA metric-type split; the ~62% figure is a practitioner estimate, not a primary dataset figure.

Aggregator solvency risk is illustrated by the Thrasio bankruptcy. Thrasio filed Chapter 11 in the District of New Jersey in February 2024, eliminating roughly $495M in debt. Coverage of the seller impact is summarized in the eGrowth Partners analysis of the Thrasio filing.

Data limitations. No public primary source publishes earnout collection rates specifically for DTC or sub-$15M ecommerce deals; the 21-cent figure is an aggregate across all non-life-sciences private M&A, and SRS Acquiom's note on sub-$50M underperformance suggests the true DTC rate is likely worse. Collection rates split by metric type (revenue vs. EBITDA) are not published; the revenue-preference conclusion reflects manipulation risk and practitioner consensus, not a measured split.

Frequently asked questions